Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 16, 2026 08:33 ET | Source: Entera Bio Ltd.

Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026

EB612, a first-in-class long-acting PTH(1-34) oral peptide for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected...
June 16, 2026 07:00 ET | Source: Pasithea

Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial

Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial
June 16, 2026 07:00 ET | Source: NovaBridge Biosciences

NovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric Cancer

Registrational Phase 3 Trial Expected to Begin as Early as Q4 2026Detailed Phase 1b Data Expected to be Presented at a Major Medical Conference in H2 2026 ROCKVILLE, Md., June 16, 2026 (GLOBE...
June 16, 2026 05:44 ET | Source: VRURC

VRURC Launches T009 Qi2 Foldable 3-in-1 Magnetic Wireless Charger, Now Available for Pre-Order at 62% Off Ahead of June 20 Release

VRURC T009 3-in-1 Qi2 mag charger for Apple. 25W fast charge, dual cooling, retractable cable. Pre-order 62% off til June 20, 2026. 2y warranty.
June 15, 2026 13:36 ET | Source: Nordicus Partners Corporation

Nordicus Partners Corporation Corporate Update

Orocidin's QR-01 demonstrates efficacy in two preclinical periodontitis models; micro-CT confirms reduced bone lossPhase IIa clinical trial in patients planned H1 2027 at the University of...
June 15, 2026 08:45 ET | Source: Entera Bio Ltd.

ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)

The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time as an oral presentation at ENDO 2026 Single tablet EB613...
June 15, 2026 07:02 ET | Source: Pasithea

Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference

Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference
June 14, 2026 10:00 ET | Source: Mineralys Therapeutics, Inc.

Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)

– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension – – Coordinated reductions...
June 12, 2026 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma to Present Preclinical Asthma and Dermatitis Data for Oral STAT6 Inhibitor REX-8756 at the European Association of Allergy and Clinical Immunology (EAACI) and Revolutionizing Atopic Dermatitis (RAD) Congresses

SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today...
June 12, 2026 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

Oral presentation at JDA features new data from the KT-621 Phase 1 study in healthy Japanese adults, with safety and PK/PD results consistent with previously reported KT-621 clinical studies KT-621...